Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2017 3
2018 1
2019 1
2020 2
2021 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Rheumatology in Ukraine.
Doskaliuk B, Zimba O, Yatsyshyn R, Kovalenko V. Doskaliuk B, et al. Among authors: yatsyshyn r. Rheumatol Int. 2020 Feb;40(2):175-182. doi: 10.1007/s00296-019-04504-4. Epub 2020 Jan 2. Rheumatol Int. 2020. PMID: 31898762 Review.
Prostate involvement in granulomatosis with polyangiitis.
Yatsyshyn R, Zimba O, Bahrii M, Doskaliuk B, Huryk V. Yatsyshyn R, et al. Rheumatol Int. 2019 Jul;39(7):1269-1277. doi: 10.1007/s00296-019-04321-9. Epub 2019 May 9. Rheumatol Int. 2019. PMID: 31073659 Review.
The interplay between rheumatic diseases and pulmonary health.
Fedorchenko Y, Zimba O, Yatsyshyn R, Doskaliuk B, Zaiats L, Fedorchenko M. Fedorchenko Y, et al. Among authors: yatsyshyn r. Rheumatol Int. 2024 Mar 20. doi: 10.1007/s00296-024-05565-w. Online ahead of print. Rheumatol Int. 2024. PMID: 38509351 Review.
Challenges in diagnosis of limited granulomatosis with polyangiitis.
Zimba O, Doskaliuk B, Yatsyshyn R, Bahrii M, Hrytsevych M. Zimba O, et al. Among authors: yatsyshyn r. Rheumatol Int. 2021 Jul;41(7):1337-1345. doi: 10.1007/s00296-021-04858-8. Epub 2021 Apr 20. Rheumatol Int. 2021. PMID: 33939014 Review.
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial.
Westhovens R, Wiland P, Zawadzki M, Ivanova D, Kasay AB, El-Khouri EC, Balázs É, Shevchuk S, Eliseeva L, Stanislavchuk M, Yatsyshyn R, Hrycaj P, Jaworski J, Zhdan V, Trefler J, Shesternya P, Lee SJ, Kim SH, Suh JH, Lee SG, Han NR, Yoo DH. Westhovens R, et al. Among authors: yatsyshyn r. Rheumatology (Oxford). 2021 May 14;60(5):2277-2287. doi: 10.1093/rheumatology/keaa580. Rheumatology (Oxford). 2021. PMID: 33230526 Free PMC article. Clinical Trial.
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
Smolen JS, Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Lee Y, Rho YH. Smolen JS, et al. Among authors: yatsyshyn r. Ann Rheum Dis. 2018 Feb;77(2):234-240. doi: 10.1136/annrheumdis-2017-211741. Epub 2017 Oct 17. Ann Rheum Dis. 2018. PMID: 29042358 Free PMC article. Clinical Trial.
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
Smolen JS, Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Choi J, Rho YH. Smolen JS, et al. Among authors: yatsyshyn r. Rheumatology (Oxford). 2017 Oct 1;56(10):1771-1779. doi: 10.1093/rheumatology/kex254. Rheumatology (Oxford). 2017. PMID: 28957563 Free PMC article. Clinical Trial.
13 results